Cedric Odje
Senior Investment Associate @ Debiopharm Innovation Fund
Cedric Odje is a Senior Investment Associate at Debiopharm Innovation Fund, where he specializes in propelling innovations in pharma R&D and oncology through pre-seed to series A investments. Leveraging his M&A background and family office experience, Cedric is also a proactive business angel and jury expert, embodying a deep-seated passionfor entrepreneurship and healthcare innovation. His strengths in conducting due diligence and board governance further solidify his role as a strategic partner in the investment ecosystem.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Cedric Odje invests in
Stages Cedric Odje invests in
Countries Cedric Odje invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 11 (73%)
- Biotechnology 7 (47%)
- Software 5 (33%)
- Life Science 5 (33%)
- Artificial Intelligence 5 (33%)
Stage
- Series A 6 (40%)
- Seed 4 (27%)
- Pre-Seed 3 (20%)
- Series C 1 (7%)
- Post-IPO Equity 1 (7%)
Country
- United States 5 (33%)
- United Kingdom 3 (20%)
- France 2 (13%)
- Israel 1 (7%)
- Germany 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AI agents to accelerate clinical development workflows for the pharma industry. | Pre-Seed / Jun 10, 2025 | ||
| Risklick is develops a first-of-the-kind data-driven tool to allow end-users to identify similar Clinical trials(CTs) and assess risks in early steps of the protocol design. CTs are used to determine the efficacy and safety of an experimental treatment; however, up to 90% of them fail in the early stage of protocol design and the nature andcomplexity of CTs make risk assessment difficult and time-consuming. | Seed / Apr 23, 2024 | ||
| ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave | Seed / Nov 29, 2023 | ||
| Patient-centric cancer data and analytics platform for translational cancer biologists | $317.4K / Pre-Seed / Oct 09, 2023 | ||
| Neuroute (neuroute.ai) is the AI-powered system for smarter clinical trials. Backed by PharmStars (Astrazeneca, Pfizer, Novo Nordisk, Boehringer Ingelheim, Takeda, Roche & Eli Lilly). Website Neuroute.ai | Seed / Sep 28, 2023 | ||
| Altis Labs is the computational imaging company advancing precision medicine. We believe that medical imaging is the richest source of untapped information. Life sciences companies use our software platform, Nota, to accelerate all stages of clinical development. Trained on over 140 million longitudinal real-world images with associated clinicalinformation, our deep learning models predict clinically meaningful outcomes to quantify treatment effect more accurately. | $6M / Seed / Jun 21, 2023 | ||
| Genialis is a computational precision medicines company that develops a clinical biomarker discovery platform. It engages in unraveling complex biology to find new ways to address disease. Its platform defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinicaldevelopment.Genialis was established in 2015 in Boston, Massachusetts by Rafael Rosengarten. | $13M / Series A / Mar 29, 2023 | ||
| Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. | $16.4M / Series A / Mar 09, 2023 | ||
| Mika is a digital platform that empowers cancer patients. It aims to help improve cancer patients' mental health and well-being. Mika was created in collaboration with leading research institutions. The company was established in 2017 and is headquartered in Berlin, Germany. | $10.6M / Series A / May 09, 2022 | ||
| VivoSense, also known as Vivonoetics are a data analysis and software company specializing in wearable sensor physiological monitoring solutions for research and clinical trials. | $25M / Series A / Mar 30, 2022 | ||
| See all 15 investments → | |||
Co-Investors
Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.
Debiopharm Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Cedric Odje
Senior Investment Associate
|
|||
|
Nicole Wilson
Senior Administrative Assistant
|
|||
Tanja Dowe
Chief Executive Officer
|
|||
Thomas Gibbs
Director
|
|||
Vincent Lepreux
Investment Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cedric Odje invest in?
Cedric Odje invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cedric Odje?
Public channels for Cedric Odje include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Cedric Odje last invest?
The most recent investment recorded for Cedric Odje closed in Jun 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
